LifeMD

LifeMD recently announced 3rd quarter 2024 results. “LifeMD’s core telehealth business had another very strong quarter, led by outperformance in both our Rex??MD and virtual primary care verticals. We not only are very pleased with our tremendous growth rate, but also with the exponential increase in sequential profitability of our telehealth business,” said Justin Schreiber, Chairman and CEO. Full details can be found on our Investor Relations website.

Announcing the official grand opening of our state-of-the-art affiliated pharmacy! This marks a major milestone in our journey to create a fully integrated, end-to-end telehealth platform. With this 22,500-square-foot facility, LifeMD can offer patients a seamless care experience, from consultation to medication delivery. This not only enhances patient convenience and satisfaction but also allows us to deliver more personalized care. Congratulations to all involved!

We are excited to announce the launch of TestoRx, a direct-to-consumer men’s hormone therapy telehealth offering. As part of our Rex MD health brand, TestoRx was designed in partnership with clinicians renowned in their field and offers multiple treatment options – alongside ongoing telehealth visits and follow-up care. Please review our press release to learn more about why we feel TestoRx is a clinically important and sought after component of our comprehensive men’s health offering.

LifeMD’s Shane Biffar, Chief Compliance Officer & Deputy General Counsel, will be highlighted as a featured speaker at Annual Health Law & Policy Forum West (Sept 30th). This event, hosted by King & Spalding, provides an insider’s look at the foremost legal and political developments that are having an impact on the healthcare industry. Shane will be providing expertise alongside King & Spalding's Dana Berkowitz, Counsel, Kyle Gotchy, Partner, and Juliet McBride, Partner, on navigating emerging legal and compliance challenges in the digital health space. This is a fantastic opportunity to showcase the depth of knowledge and leadership we have on our legal team. We look forward to a great dialogue on Monday!

Today we announced significant enhancements to the LifeMD weight management program, including: *Investments in technology to enhance the prior authorization submissions and appeals process, reducing barriers to accessing brand-name medications. *Launch of a non-GLP-1 weight management therapy that is expected to grow the program’s addressable market by approximately 15%. *Integration of at-home, self-collection laboratory testing services, making remote healthcare more inclusive. Read the full release on IR website, including commentary from Justin Schreiber, CEO, and Anthony Puopolo II, President, LifeMD Affiliated P.C.s.

LifeMD is proud to support Digital Health New York Summit 2024! This exclusive, invite-only event brings together an elite group of founders, investors, and executives to drive healthcare innovation forward. Our CEO, Justin Schreiber will be joining a panel with Holly Lofton and Antoine Robiliard, moderated by Gabriel Perna, to discuss the ways that GLP-1s, together with technology, have evolved the weight management sector. Let’s connect if you’re attending! #DHNY24?https://lnkd.in/gaf3fQgk

Anthony Puopolo II, MD, President of LifeMD Affiliated P.C.s has been featured alongside top healthcare innovators and leaders in the H1 2024 New York Healthcare Innovation Report, published by Digital Health New York! Dr. Puopolo participated in a panel at OBESITY+HEALTH, a conference highlighting pressing topics related to obesity and weight management care with a focus on actionable solutions. Read the full report now to explore the latest trends and insights emerging within the digital health community in NY and beyond. https://go.dhny.co/h1-2024

Another company milestone: today we announced the launch of commercial health insurance acceptance for primary care services, including weight management --- making LifeMD’s high-quality care more affordable and accessible, and in turn improving clinical outcomes and patient retention rates. Read more about this exciting announcement on our IR website.

LifeMD is set to join the broad-market Russell 3000(R) Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution on July 1st. The annual reconstitution captures the 4,000 largest U.S. stocks as of April 30th, ranking them by total market capitalization. “This is testament to the hard work of my LifeMD colleagues and the success we’ve had in bringing affordable primary care, weight loss and other healthcare services to a growing number of patients nationwide,” said Justin Schreiber, Chairman and CEO of LifeMD. Read more on the LifeMD IR website.

Just Released: LifeMD Reports First Quarter 2024 Results; Raises Full Year Revenue Guidance The strength of our existing businesses --- highlighted by notable subscriber growth, retention, unit economics, and recent partner announcements --- coupled with newly launching product categories under RexMD --- position LifeMD for accelerated growth and profitability in the back half of 2024 and beyond. A press release with additional details has been posted to our IR website.